AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19690278 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 6-mg hyperbaric bupivacaine 0.5%
Number of subjects: 40
Study 19690278 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia with 6-mg hyperbaric bupivacaine 0.5%
Number of subjects: 40
Study 16488895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 129
Study 16488895 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 129
Study 12717602 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline-Dexpanthenol
Number of subjects: 152
Study 12717602 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline
Number of subjects: 152
Study 10912880 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) administered orally two times a day for 27 consecutive days
Number of subjects: 54
Study 10912880 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren)
Number of subjects: 54
Study 10912880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9451346 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glycine irrigation solution at 70 cm height
Number of subjects: 40
Study 9451346 — intervention group
Group type: COMPARATOR
Intervention: 1.5% glycine irrigation solution at 150 cm height
Number of subjects: 40
Study 1587749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologically negative lymph nodes (Stage T-2 (B))
Number of subjects: 805
Study 1587749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologically negative lymph nodes (Stage T-3,4 (C))
Number of subjects: 805
Study 1587749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic positive lymph nodes (Stage T-2 (B))
Number of subjects: 805
Study 1587749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic positive lymph nodes (Stage T-3,4 (C))
Number of subjects: 805
Study 1587749 — intervention group
Group type: COMPARATOR
Intervention: Clinical positive lymph nodes
Number of subjects: 805
Study 1587749 — intervention group
Group type: COMPARATOR
Intervention: Pathologic positive lymph nodes
Number of subjects: 805
Study 3996194 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting task with low-probability stimuli (0.17)
Number of subjects: 0
Study 3996194 — intervention group
Group type: EXPERIMENTAL
Intervention: Guessing task with varying stimulus probabilities (0.17, 0.33, 0.50)
Number of subjects: 0
Study 31892533 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-0101 (5 mg/kg, every 2 weeks for 12 weeks)
Number of subjects: 90
Study 31892533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31892533 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-0101
Number of subjects: 90
Study 29856281 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 32
Study 29856281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 32
Study 29856281 — intervention group
Group type: COMPARATOR
Intervention: No enhancing intervention (Control)
Number of subjects: 32
Study 26764069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 130
Study 26764069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 25054702 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic behavior by family
Number of subjects: 66
Study 25054702 — intervention group
Group type: COMPARATOR
Intervention: Empathic behavior by nurses
Number of subjects: 66
Study 25054702 — intervention group
Group type: COMPARATOR
Intervention: No specific empathic behavior
Number of subjects: 66
Study 22354408 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese premenopausal women
Number of subjects: 54
Study 22354408 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese postmenopausal women
Number of subjects: 54
Study 22354408 — intervention group
Group type: COMPARATOR
Intervention: Healthy postmenopausal controls
Number of subjects: 54
Study 22354408 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of all postmenopausal women
Number of subjects: 54
Study 20420907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 mug taken twice daily for one week)
Number of subjects: 8
Study 20420907 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D(3) (200,000 IU weekly for 3 weeks)
Number of subjects: 8
Study 20420907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo weekly for 3 weeks)
Number of subjects: 8
Study 17936366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 89
Study 17936366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily for 90 days)
Number of subjects: 89
Study 17936366 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 89
Study 17518377 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic needle driver under joystick control for spinal nerve blockade
Number of subjects: 10
Study 17518377 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic needle driver for lung biopsy under CT fluoroscopy
Number of subjects: 10
Study 12401856 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (12 mg before each dialysis session for 4 weeks)
Number of subjects: 10
Study 12401856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12401856 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (after washout period)
Number of subjects: 10
Study 12401856 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Number of subjects: 10
Study 12401856 — intervention group
Group type: COMPARATOR
Intervention: Creatine monohydrate and placebo
Number of subjects: 10
Study 10080465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 81
Study 10080465 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study 8747025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 29
Study 8747025 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 29
Study 2387279 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenite with ascorbic acid
Number of subjects: 58
Study 2387279 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-rich pea flour
Number of subjects: 58
Study 2387279 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available preparations (yeast Se)
Number of subjects: 58
Study 2387279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 6803277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine plus L-tryptophan
Number of subjects: 20
Study 6803277 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 20
Study 31876668 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained (ET)
Number of subjects: 38
Study 30999605 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor areas
Number of subjects: 2573
Study 30999605 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor areas
Number of subjects: 2573
Study 30999605 — intervention group
Group type: EXPERIMENTAL
Intervention: Patios
Number of subjects: 2573
Study 30999605 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional smoker in patio air
Number of subjects: 2573
Study 30999605 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional smoker in indoor air
Number of subjects: 2573
Study 28522374 — intervention group
Group type: EXPERIMENTAL
Intervention: NNZ-2566 (doses ranged from 6.0 to 100mg/kg orally and 0.1 to 30mg/kg intravenously)
Number of subjects: 61
Study 28522374 — intervention group
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Number of subjects: 61
Study 25469528 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Saccharomyces boulardii)
Number of subjects: 44
Study 25469528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23404961 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 meals per day (6M)
Number of subjects: 15
Study 23404961 — intervention group
Group type: COMPARATOR
Intervention: 3 meals per day (3M)
Number of subjects: 15
Study 21091547 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg vitamin C/kg feed
Number of subjects: 0
Study 21091547 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dietary vitamin C supplementations
Number of subjects: 0
Study 21091547 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/kg or 800 mg vitamin C/kg feed
Number of subjects: 0
Study 21091547 — intervention group
Group type: EXPERIMENTAL
Intervention: 150‐800 mg vitamin C/kg feed
Number of subjects: 0
Study 19743983 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond snack
Number of subjects: 45
Study 19743983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal bar snack
Number of subjects: 45
Study 19743983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 16514568 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy
Number of subjects: 14
Study 16514568 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched cohort undergoing capsule endoscopy for suspected small bowel disease)
Number of subjects: 14
Study 15485574 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered Bicavera solution
Number of subjects: 60
Study 15485574 — intervention group
Group type: COMPARATOR
Intervention: Lactate-containing Balance solution
Number of subjects: 60
Study 11145322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg daily for 15 nights)
Number of subjects: 12
Study 11145322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 12
Study 11145322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9033462 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 415
Study 9033462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 8509532 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus retroperfusion support during balloon inflation
Number of subjects: 21
Study 3663879 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur 450 mg b.i.d.
Number of subjects: 5
Study 3663879 — intervention group
Group type: EXPERIMENTAL
Intervention: Theotrim 450 mg b.i.d.
Number of subjects: 5
Study 26712355 — intervention group
Group type: EXPERIMENTAL
Intervention: Family violence (FV)
Number of subjects: 3175
Study 26712355 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessed intimate partner violence (IPV)
Number of subjects: 3175
Study 26712355 — intervention group
Group type: EXPERIMENTAL
Intervention: Child abuse
Number of subjects: 3175
Study 26712355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying (lifetime)
Number of subjects: 3175
Study 26712355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying (preceding year)
Number of subjects: 3175
Study 26712355 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of FV and BV (lifetime)
Number of subjects: 3175
Study 26712355 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of FV and BV (preceding year)
Number of subjects: 3175
Study 27142632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical balance measures (tandem stance, standing one leg, walking in the figure of eight, walking heel to toe on a line, walking as fast as possible for 30 m, five times sit to stand)
Number of subjects: 82
Study 27142632 — intervention group
Group type: EXPERIMENTAL
Intervention: Five times sit to stand
Number of subjects: 82
Study 24716835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg twice daily for 12 weeks
Number of subjects: 418
Study 24716835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 23244402 — intervention group
Group type: EXPERIMENTAL
Intervention: New Hope antipoverty intervention
Number of subjects: 0
Study 20507310 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-PASIII-PC (platelets stored in platelet additive solution with pathogen reduction)
Number of subjects: 278
Study 20507310 — intervention group
Group type: EXPERIMENTAL
Intervention: PASIII-PC (platelets stored in platelet additive solution without pathogen reduction)
Number of subjects: 278
Study 20507310 — intervention group
Group type: COMPARATOR
Intervention: Plasma-PC (platelets stored in plasma)
Number of subjects: 278
Study 18247057 — intervention group
Group type: EXPERIMENTAL
Intervention: -1641A/-1654C haplotype carriers
Number of subjects: 240
Study 15144762 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated nets (ITNs)
Number of subjects: 0
Study 15144762 — intervention group
Group type: COMPARATOR
Intervention: In-house residual spraying (IRS)
Number of subjects: 0
Study 15144762 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ITNs to IRS
Number of subjects: 0
Study 11806592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender odor oil
Number of subjects: 42
Study 11806592 — intervention group
Group type: COMPARATOR
Intervention: No odor (control)
Number of subjects: 42
Study 11806592 — intervention group
Group type: COMPARATOR
Intervention: Nonstressful condition (control)
Number of subjects: 42
Study 9754845 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 0
Study 9754845 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HPD) with VPA
Number of subjects: 0
Study 9754845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7817331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 40
Study 7817331 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin
Number of subjects: 40
Study 3044091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir capsules, five times per day for five days
Number of subjects: 0
Study 3044091 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5 percent acyclovir in a modified aqueous cream base
Number of subjects: 0
Study 3044091 — intervention group
Group type: COMPARATOR
Intervention: Topical 5 percent acyclovir in a polyethylene base
Number of subjects: 0
Study 3044091 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of oral acyclovir
Number of subjects: 0
Study 30483832 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFL reconstruction with lateral retinacular release (LRR)
Number of subjects: 33
Study 30483832 — intervention group
Group type: COMPARATOR
Intervention: MPFL reconstruction without lateral retinacular release (no LRR)
Number of subjects: 33
Study 28758078 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoposterior transforaminal epidural steroid injection (SP TFESI) with 1 mL of contrast material followed by steroid injection
Number of subjects: 31
Study 26311810 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d creatine
Number of subjects: 458
Study 26311810 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d creatine plus 400 μg/d folic acid
Number of subjects: 458
Study 26311810 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg/d folic acid
Number of subjects: 458
Study 26311810 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 458
Study 24063842 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management counseling in patients with HFpEF
Number of subjects: 902
Study 24063842 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics in patients with HFrEF
Number of subjects: 902
Study 22011650 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1217
Study 22011650 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel
Number of subjects: 1217
Study 18511215 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal pelvic floor exercise (8 sessions with a physiotherapist between 6 and 8 months of pregnancy)
Number of subjects: 280
Study 18511215 — intervention group
Group type: COMPARATOR
Intervention: Sole written instructions
Number of subjects: 280
Study 17149461 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased access to spirometry in asthma education centres (AECs) during the second six-month period.
Number of subjects: 303
Study 17149461 — intervention group
Group type: COMPARATOR
Intervention: No spirometry offered in AECs during the study.
Number of subjects: 303
Study 12492792 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.2% plus sufentanil 0.2 micro g ml‐1, at 5 ml h‐1
Number of subjects: 60
Study 12492792 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral block with the same analgesic mixture
Number of subjects: 60
Study 12492792 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraarticular infusion of ropivacaine 0.2% plus sufentanil 0.2 micro g ml‐1, at 5 ml h‐1
Number of subjects: 60
Study 10692189 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg up to 2 mg)
Number of subjects: 104
Study 10692189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 10692189 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 104
Study 9348574 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 400 mg/day for 6 months plus prednimustine 60 mg/m2 for 7 consecutive days, every 28 days in 6 cycles (arm B)
Number of subjects: 409
Study 9348574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 1 year plus UFT 400 mg/day for 6 months (arm B)
Number of subjects: 409
Study 9348574 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day for 1 year (arm A)
Number of subjects: 409
Study 8122356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.1 mg/kg bw intramuscularly at 8‐h intervals)
Number of subjects: 70
Study 3537899 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyazide (50 mg triamterene and 25 mg hydrochlorothiazide)
Number of subjects: 33
Study 3537899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30058731 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold diode micropulse (SDM) laser
Number of subjects: 68
Study 30058731 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 68
Study 30383531 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) application during ACL reconstruction (Group 1)
Number of subjects: 40
Study 30383531 — intervention group
Group type: COMPARATOR
Intervention: Control group without PRF application (Group 2)
Number of subjects: 40
Study 30383531 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) application (Group 1)
Number of subjects: 40
Study 27364321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity running trials (500m, 1000m, 1500m) at 90% of maximal speed
Number of subjects: 6
Study 24099704 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Online Learning (AOL)
Number of subjects: 216
Study 24099704 — intervention group
Group type: COMPARATOR
Intervention: Passive Online Learning (POL)
Number of subjects: 216
Study 22019482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 4656
Study 22019482 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 4656
Study 20164315 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk (16.98 mg genistein and 5.40 mg daidzein aglycone equivalents per dose)
Number of subjects: 31
Study 20164315 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplement (5.27 mg genistein and 17.56 mg daidzein aglycone equivalents per dose)
Number of subjects: 31
Study 20164315 — intervention group
Group type: COMPARATOR
Intervention: Control (no soy isoflavones)
Number of subjects: 31
Study 18788506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 1 g q12 h and clindamycin 900 mg q8 h (group 2)
Number of subjects: 140
Study 18788506 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g q12 h and clindamycin 900 mg q8 h (group 1)
Number of subjects: 140
Study 16128647 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable drug delivery system (IDDS)
Number of subjects: 30
Study 16128647 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive medical management (CMM)
Number of subjects: 30
Study 11892681 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment using TherMatrx TMx-2000
Number of subjects: 200
Study 11892681 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 200
Study 9578059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell support
Number of subjects: 218
Study 9578059 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose salvage chemotherapy
Number of subjects: 218
Study 7510351 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million kallikrein inactivator units of aprotinin (high-dose group)
Number of subjects: 45
Study 7510351 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 million kallikrein inactivator units of aprotinin (low-dose group)
Number of subjects: 45
Study 7510351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 45
Study 7510351 — intervention group
Group type: COMPARATOR
Intervention: All groups (high-dose, low-dose, control)
Number of subjects: 45
Study 2573113 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 75
Study 2573113 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 75
Study 2573113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 4395906 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline 400 μg
Number of subjects: 0
Study 4395906 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 0
Study 4395906 — intervention group
Group type: EXPERIMENTAL
Intervention: Other bronchodilator aerosols (doses adjusted to match peak response of isoprenaline)
Number of subjects: 0
Study 30312378 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods 1 (weighting methods based on simulated individual data)
Number of subjects: 0
Study 30312378 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods 2 (method of moments)
Number of subjects: 0
Study 30312378 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3 (weighted trial's subgroup-specific treatment effects)
Number of subjects: 0